Johnson & Johnson 2008 Annual Report (10-K) Summary
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 28, 2008. Johnson & Johnson is a holding company with over 250 operating companies and approximately 118,700 employees worldwide. The company operates through three primary segments: Consumer (baby care, skin care, oral care, etc.), Pharmaceutical (prescription drugs across various therapeutic areas), and Medical Devices and Diagnostics (surgical, orthopaedic, and diagnostic products). The company is incorporated in New Jersey and trades on the New York Stock Exchange.
Key Financial Metrics
Note: Specific consolidated revenue, net income, cash flow, and debt figures are incorporated by reference to the Annual Report to Shareholders (Exhibit 13) and are not explicitly detailed in the provided text. The following metrics are available from the filing text:
- Research and Development (R&D) Expenses: $7.6 billion for fiscal 2008 (compared to $7.7 billion in 2007 and $7.1 billion in 2006).
- Stock Repurchases: Since the inception of the program on July 9, 2007, the company purchased 124,850,500 shares for a total of $8.1 billion as of December 28, 2008.
- Q4 2008 Repurchases: 14,042,700 shares purchased in the fourth quarter, with an average price ranging from $57.80 to $65.78 per share.
- Valuation Accounts (Schedule II): Total valuation and qualifying accounts (including accrued rebates, returns, promotions, and reserves for doubtful accounts) totaled $3,304 million at the end of 2008.
- Product Concentration: REMICADE accounted for approximately 6% of total revenues, and TOPAMAX accounted for 4% in 2008.
Material Changes and Operational Highlights
- Patent Expirations: Significant patents for RISPERDAL (expired Dec 2007) and TOPAMAX (expired Sept 2008) expired during the period. Pediatric extensions granted market exclusivity through June 2008 and March 2009, respectively. The next major expiration is LEVAQUIN in December 2010.
- Executive Changes: Christine A. Poon, Vice Chairman of the Board, announced plans to retire in March 2009. Alex Gorsky joined the Executive Committee in January 2009 as Worldwide Chairman, Surgical Care Group.
- Manufacturing Footprint: The company operates 147 manufacturing facilities totaling approximately 21.6 million square feet globally.
Guidance, Risks, and Contingencies
Regulatory and Legal Risks: The company faces increasing scrutiny regarding healthcare costs, drug pricing, and business practices. Regulatory agencies have powers to enforce product withdrawals, recalls, and sanctions. The company is involved in various legal proceedings, including environmental remediation under the Superfund Act, though management does not expect a material adverse effect.
Market and Operational Risks: International operations are subject to political uncertainties and restrictive economic policies. Competition is strong across all product lines, requiring substantial investment in R&D and marketing. The company notes that spending is typically heavier in the fourth quarter due to advertising and R&D activities.
Capital Allocation: The company maintains a stock repurchase program authorized for up to $10 billion, funded by available cash and debt, with no expectation of affecting its triple-A credit rating.
Investor Verification Checklist
- Verify the full consolidated revenue, net income, and cash flow figures in the Annual Report to Shareholders (Exhibit 13), as they are not explicitly listed in the 10-K text provided.
- Review the Legal Proceedings (Note 18) in the Annual Report for details on specific litigation risks and potential liabilities.
- Assess the impact of the patent expirations for TOPAMAX and RISPERDAL on future Pharmaceutical segment revenue.
- Monitor the execution of the $10 billion stock repurchase program and its effect on liquidity and share count.
- Confirm the status of regulatory investigations and environmental compliance costs referenced in the Risk Factors and Legal Proceedings sections.